Company Of The Day: Medtronic
What?
Medtronic (NYSE:MDT) posted a mixed set of Q3 FY’22 results. While revenues missed expectations, remaining roughly flat year-over-year at $7.8 billion, adjusted EPS was in-line with estimates at $1.37. Guidance for Q4 was also in-line with estimates.
Why?
- Will Medtronic Stock See Higher Levels?
- Will Medtronic Stock See Higher Levels Following Its Q4 Results?
- Here’s What Makes Medtronic Stock A Better Pick Over This Pharmaceuticals Company
- Is There A Better Pick Over Medtronic Stock?
- This Medical Devices Company Is Likely To Offer Better Returns Over Medtronic Stock
- What To Expect From Medtronic’s Q3?
The sales of some devices, such as its pelvic health products were impacted as the surge in omicron virus cases resulted in deferred procedures in Q3. However, the company says that it is seeing improving volumes with demand for its heart devices remaining strong.
So What?
Medtronic stock gained almost 3% in Tuesday’s trading.
See Our Complete Analysis For Medtronic
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.
| Returns | Feb 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| MDT Return | 0% | 0% | 46% |
| S&P 500 Return | -5% | -10% | 92% |
| Trefis MS Portfolio Return | -3% | -12% | 246% |
[1] Month-to-date and year-to-date as of 2/23/2022
[2] Cumulative total returns since the end of 2016